These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20002336)

  • 1. The impact of B-type natriuretic peptide, New York Heart Association classification and depression on quality of life in nonhospitalized heart failure patients.
    Ancheta IB; Battie C; Cobb S; Ancheta C; Miller A; Chiong JR
    Prog Cardiovasc Nurs; 2009 Dec; 24(4):124-30. PubMed ID: 20002336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression is a major determinant of quality of life in patients with chronic systolic heart failure in general practice.
    Müller-Tasch T; Peters-Klimm F; Schellberg D; Holzapfel N; Barth A; Jünger J; Szecsenyi J; Herzog W
    J Card Fail; 2007 Dec; 13(10):818-24. PubMed ID: 18068614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does clinician's knowledge of B-type natriuretic peptide levels translate to improvement of quality of life and less hospitalization days in patients with heart failure?
    Ancheta IB; Evans M; Miller AB; Chiong JR; Battie C
    Prog Cardiovasc Nurs; 2009 Mar; 24(1):12-8. PubMed ID: 19261138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients.
    Hogenhuis J; Jaarsma T; Voors AA; Hillege HL; Lesman I; van Veldhuisen DJ
    Int J Cardiol; 2006 Mar; 108(1):63-7. PubMed ID: 16516699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in B-type natriuretic peptides after surgical ventricular restoration.
    Sartipy U; Albåge A; Larsson PT; Insulander P; Lindblom D
    Eur J Cardiothorac Surg; 2007 May; 31(5):922-8. PubMed ID: 17321144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].
    Zhao XY; Yang YJ; Zhang J; Dang AM; Ni XH; Huang J; Kang S; Ma WH; Zhao DY
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(17):1165-9. PubMed ID: 16796855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
    Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
    Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients.
    Boffa GM; Zaninotto M; Bacchiega E; Nalli C; Forni M; Tiso E; Cacciavillani L; Razzolini R; Plebani M
    Ital Heart J; 2005 Feb; 6(2):125-32. PubMed ID: 15819505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure.
    Fontanive P; Saponati G; Iurato A; Volterrani C; Boni A; Piccioni L; Dini FL;
    Med Sci Monit; 2009 Dec; 15(12):CR606-11. PubMed ID: 19946230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between thoracic fluid content and natriuretic peptide type B in patients with systolic heart failure.
    Balak W; Sinkiewicz W; Gilewski W; Karasek D; Błazejewski J; Dudziak J
    Kardiol Pol; 2009 Nov; 67(11):1220-5. PubMed ID: 20024849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study.
    Wu AH; Omland T; Wold Knudsen C; McCord J; Nowak RM; Hollander JE; Duc P; Storrow AB; Abraham WT; Clopton P; Maisel AS; McCullough PA;
    Am J Hematol; 2005 Nov; 80(3):174-80. PubMed ID: 16247751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
    Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
    J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
    Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
    J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
    De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
    J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators.
    Masson S; Gorini M; Salio M; Lucci D; Latini R; Maggioni AP
    Ital Heart J; 2000 Apr; 1(4):282-8. PubMed ID: 10824729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.